Literature DB >> 2015706

Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A.

C Horrocks1, J I Duncan, A M Oliver, A W Thomson.   

Abstract

Normal skin of healthy individuals and both lesional and uninvolved skin from patients with psoriasis before and after receiving cyclosporin A (CsA; 2.5 or 5 mg/kg per day) was examined by immunocytochemistry for differences in expression of adhesion-relevant epitopes. Normal, lesional and uninvolved skin all showed staining of basal keratinocytes for CD29 (the common beta chain of the beta 1-integrin family). No other adhesion molecule investigated was detected on structural components of normal skin. In uninvolved skin, weak expression of CD54 (intercellular adhesion molecule 1, ICAM-1) was noted on vascular endothelium. Uninvolved keratinocytes were found to stain with anti-CD58 (leucocyte function-associated antigen 3, LFA-3) and there was weak expression of CD11b (alpha chain of complement C3bi receptor) and CD11c (alpha chain of p150, 95 molecule) but not CD11a (leucocyte function-associated antigen 1, LFA-1, alpha chain) on those cells. In lesional skin, in addition to expression of CD58, there was also enhanced expression of CD11c. Weak expression of CD54 on keratinocytes was also observed. Lesional blood vessels were found to stain strongly with anti-CD54, CD29 and CD58. CD11a was expressed only on infiltrating mononuclear cells. CsA treatment produced marked clinical improvement, accompanied by the loss of CD54 expression on keratinocytes. However, despite the loss of T cells from lesional skin with CsA treatment, CD54 persisted on blood vessels. CsA was found to have no effect on keratinocyte expression of CD29, CD58 or CD11b and c. The persistence of CD54 on vascular endothelium and of adhesion molecule expression on keratinocytes, despite resolution of the skin lesions, may explain the universal and rapid recurrence of psoriasis on cessation of CsA administration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015706      PMCID: PMC1535371          DOI: 10.1111/j.1365-2249.1991.tb08140.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience.

Authors:  M S Fradin; C N Ellis; J J Voorhees
Journal:  Br J Dermatol       Date:  1990-06       Impact factor: 9.302

2.  Intercellular adhesion molecule expression in the evolving human cutaneous delayed hypersensitivity reaction.

Authors:  R E Lewis; M Buchsbaum; D Whitaker; G F Murphy
Journal:  J Invest Dermatol       Date:  1989-11       Impact factor: 8.551

Review 3.  Mechanisms of cutaneous inflammation. Interactions between epidermal cytokines, adhesion molecules, and leukocytes.

Authors:  T S Kupper
Journal:  Arch Dermatol       Date:  1989-10

4.  Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses.

Authors:  J J Voorhees
Journal:  Arch Dermatol       Date:  1983-07

5.  Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis.

Authors:  C Horrocks; J I Duncan; H F Sewell; A D Ormerod; A W Thomson
Journal:  J Autoimmun       Date:  1990-10       Impact factor: 7.094

6.  Interferon in suction blister fluid from psoriatic lesions.

Authors:  J R Bjerke; J K Livden; M Degré; R Matre
Journal:  Br J Dermatol       Date:  1983-03       Impact factor: 9.302

7.  Four years of experience with cyclosporin A for psoriasis.

Authors:  A V Powles; B S Baker; H Valdimarsson; B Hulme; L Fry
Journal:  Br J Dermatol       Date:  1990-06       Impact factor: 9.302

Review 8.  The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognition.

Authors:  M W Makgoba; M E Sanders; S Shaw
Journal:  Immunol Today       Date:  1989-12

9.  Human epidermal basal keratinocytes express CDw29 antigens.

Authors:  M J Staquet; C Dezutter-Dambuyant; G Zambruno; D Schmitt
Journal:  Br J Dermatol       Date:  1989-11       Impact factor: 9.302

10.  Lymphokine gene expression in vivo is inhibited by cyclosporin A.

Authors:  A Granelli-Piperno
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

View more
  9 in total

1.  Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study.

Authors:  A W Thomson; M Nalesnik; K Abu-Elmagd; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis.

Authors:  L Kowalzick; K Neuber; M Weichenthal; I Köhler; J Ring
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Antigen presentation by keratinocytes directs autoimmune skin disease.

Authors:  Lian Fan; Brian W Busser; Traci Q Lifsted; Mohamed Oukka; David Lo; Terri M Laufer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  Clinical improvement in psoriasis during dithranol/UVB therapy does not correspond with a decrease in elevated serum soluble ICAM-1 levels.

Authors:  L Kowalzick; H Bildau; K Neuber; I Köhler; J Ring
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.

Authors:  B D Edwards; S M Andrew; J B O'Driscoll; R J Chalmers; F W Ballardie; A J Freemont
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

7.  A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.

Authors:  H HogenEsch; M J Gijbels; E Offerman; J van Hooft; D W van Bekkum; C Zurcher
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

8.  IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy.

Authors:  B H Lemster; P B Carroll; H R Rilo; N Johnson; A Nikaein; A W Thomson
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

9.  Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin.

Authors:  O J de Boer; I M Wakelkamp; S T Pals; N Claessen; J D Bos; P K Das
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.